India's pharmaceutical exports rose 3% to $8.04 billion in Q2 2027-28, driven by strong demand in European markets, ...
In response to safety issues surrounding cough syrups in India, the CDSCO mandates strict monitoring of high-risk solvents ...
Eli Lilly, known for its blockbuster weight-loss and anti-diabetes drugs, is now focusing on neurosciences, with significant ...
Discover how India is addressing cancer drug affordability with a new pricing strategy that aims to lower costs for patients ...
Despite beating quarterly sales and profit expectations, GSK's stock fell due to concerns over its drug pipeline and weak ...
Eli Lilly has announced that its experimental obesity drug, retatrutide, has outperformed Novo's Ozempic in a Phase 3 trial, ...
The Indian Patent Office has rejected a patent application for the BPaL regimen, a groundbreaking treatment for ...
Piramal Pharma reduces reliance on Chinese raw materials to single-digit levels to enhance supply-chain resilience amid geopolitical tensions. Chairperson Nandini Piramal discusses the company's ...
Sandoz, the Swiss generic drugmaker, adjusts its sales growth forecast to 5-6% due to supply constraints, impacting investor ...
The CDSCO has raised a public alert regarding a counterfeit batch of the liver medication Defitelio, prompting patients to ...
Despite a $2.2 billion setback due to failed drug trials, Novartis raises its profit forecast for the year, highlighting ...
Cipla targets a first wave launch of its Keytruda biosimilar QL2107 in the US after patent expiry in 2029, with expectations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results